![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
Abstract
Four different “club drugs” are reviewed: MDMA (methylenedioxymethamphetamine, “Ecstasy”), GHB (gamma-hydroxybutyrate), ketamine, and Rohypnol® (flunitrazepam). The neurobiology, clinical pharmacology, and treatment issues for each are discussed.
Additional information
Notes on contributors
Gena Covell Britt
Elinore McCance-Katz, Ph.D., is Professor of Psychiatry at Virginia Commonwealth University. She specializes in the treatment of substance use disorders in those with infectious diseases, particularly HIV disease.
Elinore F. McCance-Katz
Gena Covell Britt, Ph.D., is Assistant Professor of Psychiatry at Virginia Commonwealth University. She has been doing research in the substance abuse field for the past 11 years.